LPTX
Income statement / Annual
Last year (2024), Leap Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Leap Therapeutics, Inc.'s net income was -$67.56 M.
See Leap Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$1.50 M |
$10.05 M |
$9.68 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$427.00 K
|
$0.00
|
$0.00
|
$4.93 M
|
$4.56 M
|
$49.00 K
|
$48.00 K
|
$25.00 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$427.00 K
|
$0.00
|
$1.50 M
|
$5.12 M
|
$5.12 M
|
-$49.00 K
|
-$48.00 K
|
-$25.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
0.51
|
0.53
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$57.21 M
|
$73.23 M
|
$44.97 M
|
$32.16 M
|
$1.43 M
|
$1.13 M
|
$21.07 M
|
$22.50 M
|
$23.29 M
|
$15.37 M
|
| General & Administrative Expenses |
$12.85 M
|
$13.81 M
|
$11.80 M
|
$10.77 M
|
$4.58 M
|
$4.46 M
|
$8.92 M
|
$9.85 M
|
$4.23 M
|
$5.72 M
|
| Selling & Marketing Expenses |
$0.00
|
-$427.00 K
|
$0.00
|
$0.00
|
$2.44 M
|
$2.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.85 M
|
$13.38 M
|
$11.80 M
|
$10.77 M
|
$7.02 M
|
$7.44 M
|
$8.92 M
|
$9.85 M
|
$4.23 M
|
$5.72 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$118.00 K
|
$34.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$70.06 M
|
$86.61 M
|
$56.76 M
|
$42.93 M
|
$8.57 M
|
$8.60 M
|
$30.00 M
|
$32.35 M
|
$27.52 M
|
$21.09 M
|
| Cost And Expenses |
$70.06 M
|
$87.04 M
|
$56.76 M
|
$42.93 M
|
$13.50 M
|
$13.16 M
|
$30.00 M
|
$32.35 M
|
$27.52 M
|
$21.09 M
|
| Interest Income |
$3.13 M
|
$4.03 M
|
$925.00 K
|
$9.00 K
|
$93.00 K
|
$313.00 K
|
$447.00 K
|
$170.00 K
|
$2.00 K
|
$156.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$54.00 K
|
$41.00 K
|
$39.00 K
|
$23.00 K
|
$19.00 K
|
$121.00 K
|
$1.23 M
|
$18.00 K
|
| Depreciation & Amortization |
$5.00 K
|
$427.00 K
|
$16.00 K
|
$29.00 K
|
$210.00 K
|
$206.00 K
|
$49.00 K
|
$48.00 K
|
$25.00 K
|
$474.00 K
|
| EBITDA |
-$70.05 M |
-$80.99 M |
-$54.38 M |
-$40.54 M |
-$3.23 M |
-$3.27 M |
-$23.05 M |
-$29.72 M |
-$24.37 M |
-$11.92 M |
| EBITDA Ratio |
0
|
0
|
0
|
-27.03
|
-0.32
|
-0.34
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-27.62
|
-0.34
|
-0.36
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.09 M
|
$5.63 M
|
$2.31 M
|
$815.00 K
|
$59.00 K
|
$30.00 K
|
$7.63 M
|
$2.47 M
|
$1.89 M
|
$9.04 M
|
| Income Before Tax |
-$66.97 M
|
-$81.41 M
|
-$54.45 M
|
-$40.61 M
|
-$3.39 M
|
-$3.45 M
|
-$23.12 M
|
-$29.88 M
|
-$25.63 M
|
-$20.95 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-27.07
|
-0.34
|
-0.36
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$585.00 K
|
$0.00
|
$147.00 K
|
-$24.00 K
|
$0.00
|
$0.00
|
$20.00 K
|
-$157.00 K
|
$0.00
|
$152.00 K
|
| Net Income |
-$67.56 M
|
-$81.41 M
|
-$54.60 M
|
-$40.59 M
|
-$3.39 M
|
-$3.45 M
|
-$23.14 M
|
-$29.73 M
|
-$25.63 M
|
-$21.10 M
|
| Net Income Ratio |
0
|
0
|
0
|
-27.06
|
-0.34
|
-0.36
|
0
|
0
|
0
|
0
|
| EPS |
-1.81 |
-3.98 |
-4.82 |
-4.73 |
-4.64 |
-14.57 |
-16.36 |
-32.45 |
-27.29 |
-12.37 |
| EPS Diluted |
-1.81 |
-3.98 |
-4.82 |
-4.73 |
-4.64 |
-14.57 |
-16.05 |
-32.35 |
-27.29 |
-12.37 |
| Weighted Average Shares Out |
$37.55 M
|
$20.45 M
|
$11.32 M
|
$8.58 M
|
$5.93 M
|
$2.26 M
|
$1.41 M
|
$916.18 K
|
$939.24 K
|
$1.71 M
|
| Weighted Average Shares Out Diluted |
$37.55 M
|
$20.45 M
|
$11.32 M
|
$8.58 M
|
$5.93 M
|
$2.26 M
|
$1.44 M
|
$918.86 K
|
$939.24 K
|
$1.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
